Vir Biotechnology reports expanded Phase 2 SOLSTICE data for elebsiran, tobevibart in chronic hepatitis delta

Vir Biotechnology announced expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta, showing 100% (28/28) undetectable HDV RNA at week 96 and 100% (10/10) sustained viral response after treatment discontinuation.

Detected & updated continuously · Source: Nebula